打开APP

默克抗脑肿瘤药物Cilengitide三期临床试验失败

  1. cilengitide
  2. 默克

来源:生物谷 2013-03-04 14:15

2013年2月21日讯 /生物谷BIOON/ --德国默克公司宣告其开发的一种治疗侵袭性脑肿瘤的实验性药物——Cilengitide三期临床试验失败,未能提高胶质母细胞瘤患者的生存率。 Cilengitide作为整合酶抑制剂,它在这类新型靶向抗癌疗法中是最先进入三期临床研究的。 两年前,该公司MS药物cladribine失败后,该公司的研发似乎一直一蹶不振。

2013年2月21日讯 /生物谷BIOON/ --德国默克公司宣告其开发的一种治疗侵袭性脑肿瘤的实验性药物——Cilengitide三期临床试验失败,未能提高胶质母细胞瘤患者的生存率。

Cilengitide作为整合酶抑制剂,它在这类新型靶向抗癌疗法中是最先进入三期临床研究的。

两年前,该公司MS药物cladribine失败后,该公司的研发似乎一直一蹶不振。癌症疫苗Stimuvax也在III期失败。(生物谷Bioon.com)

英文原文:

Merck’s investigational integrin inhibitor cilengitide did not meet its primary endpoint in the CENTRIC Phase III trial evaluating if the agent could prolong overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy). The randomized, controlled, multicenter, open-label trial, conducted in partnership with the European Organisation for Research and Treatment of Cancer (EORTC), assessed the safety and efficacy of cilengitide treatment in more than 500 patients with newly diagnosed glioblastoma and methylated-methylguanine-DNA methyltransferase (MGMT) gene promoter status from 23 countries worldwide. The results of the trial will be presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting and submitted for publication in a peer-reviewed journal.

Patient safety in the CENTRIC trial was monitored frequently by an independent data monitoring committee. There were no new or unexpected safety concerns reported. In prior clinical studies, the most frequently reported adverse events attributed to cilengitide were nausea and fatigue.

“These results illustrate how challenging this disease remains, and that thorough clinical investigations like in this study are crucial before adopting new treatment strategies,” said the lead investigator and president of the EORTC Professor Roger Stupp in a press statement. “Nevertheless, the unique collaboration between academia and industry was key in establishing molecular tumor characterization towards personalized medicine. And it allows for investigation of mechanisms of disease, and identifying novel targets and combinations for the future. We remain committed to addressing the needs of patients suffering from this rare disease and will continue to investigate other treatment options.”

In the same statement, Dr. Annalisa Jenkins, head of global drug development and medical for Merck, commented, "The results of CENTRIC are disappointing, especially for people who are fighting this devastating and difficult to treat cancer. Over the coming months, we intend to analyze the data sets and ensure appropriate public disclosure of key information that will serve future scientific research related to targeted therapies in oncology. For a complete picture, we will also evaluate the results of the currently ongoing Phase II CORE trial, which included only patients with an unmethylated MGMT gene promoter status. We remain committed to advancing our pipeline and developing new treatment options in oncology for patients with high medical need.”

Merck is developing cilengitide as an anticancer therapy. The agent is thought to target certain integrins over-expressed or aberrantly expressed in many cancers that are involved in tumor cell growth and the formation of new tumor-related blood vessels in the tumor microenvironment. Cilengitide is currently being evaluated for the treatment of glioblastoma in a Phase III trial (CENTRIC) and in a Phase II trial (CORE). An additional Phase I/II trial is ongoing in patients with non-small cell lung cancer (NSCLC). Further trials are being conducted by the US National Cancer Institute (NCI).

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->